the aid library

LIST OPTIONS

CH 4: Antidepressants among adolescents with moderate-severe depressive disorder for whom psychosocial interventions have proven ineffective

World Health Organization (2015) C_WHO

(2015) Scoping question: Are antidepressants (specifically, tricyclic antidepressants and selective serotonin reuptake inhibitors) effective and safe in adolescents with moderate-severe depressive disorder for whom psychosocial interventions have proven ineffective?

Recovery-oriented psychosocial strategies enhancing independent living and social skills (such as life skills and social skills training)

World Health Organization WHO (2015) C_WHO

Q11. SCOPING QUESTIONS: In people with psychotic disorders (including schizophrenia and bipolar disorder) are recovery-oriented psychosocial strategies enhancing independent living and social skills (such as life skills and social skills training) feasible and effective?

Recovery-oriented strategies enhancing vocational and economic inclusion (such as supported employment)

World Health Organization WHO (2015) C_WHO

Q12. SCOPING QUESTION: In people with psychotic disorders, including schizophrenia and bipolar disorder, are recovery-oriented strategies enhancing vocational and economic inclusion (such as supported employment) feasible and effective?

Second-generation antipsychotic medications for psychotic disorders (including schizophrenia)
recommended

World Health Organization WHO (2012) C_WHO

Q14. SCOPING QUESTION: In adults with psychotic disorders (including schizophrenia), what is the comparative effectiveness and safety of second-generation antipsychotic medications?

Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV - Interim Guidelines

World Health Organization (WHO) World Health Organization (WHO) (2018) C_WHO

Supplement to the 2016 consolidated Guidelines on the use of antiretroviral drugs for Treating and Preventing HIV infection HIV Treatment

HEARTS. Technical package for cardiovascular disease management in primary health care. Evidence-based treatment protocols

World Health Organization WHO, et al. (2018) C_WHO

In many low- and middle-income countries, there is a wide gap between evidencebased recommendations and current practice. Treatment of major CVD risk factors remains suboptimal, and only a minority of patients who are treated reach their target levels for blood pressure, blood sugar and blood choles... more

HEARTS. Technical package for cardiovascular disease management in primary health care. Healthy-living Counselling

World Health Organization WHO, et al. (2018) C_WHO

HEARTS. Technical package for cardiovascular disease management in primary health care. Access to essential medicines and technology

World Health Organization WHO, et al. (2018) C_WHO

Procurement and supply management activities are fundamental to consistent and reliable access to essential medicines and health products. To reduce the impact of CVD, action needs to be taken to improve prevention, diagnosis, care and management of CVD diseases. Affordable essential medicines and t... more

HEARTS. Technical package for cardiovascular disease management in primary health care. Team-based care

World Health Organization WHO, et al. (2018) C_WHO

Many low-resource settings have a shortage of physicians and health workers. (1) In order to provide patient-centred continuous care more effectively, primary care systems can include team-based care strategies in their clinic workflows and protocols. Team-based care uses multidisciplinary teams (wh... more

HEARTS. Technical package for cardiovascular disease management in primary health care. Systems of Monitoring

World Health Organization WHO, et al. (2018) C_WHO

Monitoring is a crucial element in any successful programme. It is important to know if health care facilities – and ultimately countries – are meeting the agreed goals and objectives for preventing and managing cardiovascular diseases (CVD). Monitoring is the on-going collection, management ...and use of information to assess whether an activity or programme is proceeding according to plan and/ or achieving defined targets. Not all outcomes of interest can be monitored. Clear outcomes must be identified that relate to the most important changes expected to result from the project and to what is realistic and measurable within the timescale of the project. Once these outcomes have been articulated, indicators can be chosen that best measure whether the desired outcomes are being met. To allow progress to be monitored, this module provides a set of indicators on CVD management. Agreeing on a set of indicators allows countries to compare progress in CVD management and treatment across different districts or subnational jurisdictions, as well as at a facility level, identify where performance can be improved, and track trends in implementation over time. Monitoring these indicators also helps identify problems that may be encountered so that implementation efforts can be redirected. This module starts from the collection of data at facility level, which is then “transferred up” the system: facility-level data are aggregated at subnational level to produce reports that allow tracking of facility and subnational performance over time and allow for comparison among facilities. National-level data are obtained through population-based surveys. Implementing a monitoring system requires action at many levels. At national and subnational levels, staff can determine how best to integrate data elements into existing data collection systems – such as the routine service-delivery data that are collected through facility-level Health Management Information Systems (HMIS). In the facility setting, personnel must be aware of what data are needed. Sample data-collection tools are included, recognizing that countries use different datamanagement systems for HMIS, so the CVD monitoring tools will be adapted to work with the HMIS system being used by the country, such that the indicators can be collected with minimal disruption/work to existing systems and tools more

Prevention and Treatment of HIV ands other sexually transmitted infections among men who have sex with men and transgender people

World Health Organization; UNAIDS; UNDP; et al. (2011) C_WHO

Recommendations for a public health approach HIV/AIDS Programme

Prévention et traitement de l'infection à VIH et des autres infections sexuellement transmissibles chez les hommes ayant des rapports sexuels avec d'autres hommes et chez les personnes transgenres

Organisation mondiale de la Santé (World Health Organization); UNAIDS; UNDP; et al. (2011) C_WHO

Recommandations pour une approche de santé publique Programme VIH/SIDA

Q&A: Antibiotic resistance: where does it come from and what can we do about it?

Wright G.D. BMC Biology (2010) C2

Historically, the discovery of the sulfa drugs in the 1930s and the subsequent development of penicillin during World War II ushered in a new era in the treatment of infectious diseases. Infections that were common causes of death and disease in the pre-... more

Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis
recommended

Chu, D.K.; E.A Akl, S. Duda, et al. (2020) CC

a systematic review and meta-analysis Derek K Chu et al. on behalf of the COVID-19 Systematic Urgent Review Group Effort (SURGE) study authors. Published: The Lancet June 01, 2020 DOI: https://doi.org/10.1016S0140-6736(20)31142-9 'We did a systematic review of 172 observational studies in health-... more

WHO guidelines for the use of thermal ablation for cervical pre-cancer lesions

World Health Organization (2019) C_WHO

It is estimated that more than 311 000 women die of cervical cancer each year. Of these deaths, 91% occur in low- and middle-income countries. Demographic changes and a lack of action mean that the number of deaths per year is projected to reach 460 000 by 2040.

Corticosteroids for COVID-19

World Health Organization WHO (2020) C_WHO

WHO published guidance for clinicians and health care decision-makers on the use of corticosteroids in patients with COVID-19. We recommend systemic corticosteroids for the treatment of patients with severe and critical COVID-19. We suggest not to use corticosteroids in the treatment of patients ... more

Trends in prevalence of blindness and distance and near vision impairment over 30 years: an analysis for the Global Burden of Disease Study

GBD 2019 Blindness and Vision Impairment Collaborator The Lancet (2020) CC

Lignes directrices unifiées de l’OMS sur la tuberculose : module 4 : traitement : traitement de la tuberculose pharmacorésistante

Organisation Mondiale de la Santé OMS (2020) CC

Practice Education in Nursing

Registered Nurses’ Association of Ontario (RNAO) (2016) CC

The purpose of this Guideline is to provide evidence-based recommendations that promote and sustain the undergraduate nursing student’s application of knowledge to practice in a variety of clinical learning environments. The Guideline explores the relationships among and between students and nursi... more

Керівництво mhGAP: для ведення психічних, неврологічних розладів і розладів, пов'язаних зі вживанням психоактивних речовин, у неспеціалізованих закладах охорони здоров'я
recommended

Tarun Dua, Nicolas Clark, Neerja Chowdhary et al. World Health Organisation (WHO) (2016) C_WHO

mhGAP Intervention Guide Mental Health Gap Action Programme Version 2.0 for mental, neurological and substance use disorders in non-specialized health settings The key updates include: content update in various sections based on new evidence; design changes for enhanced usability; a streamlined and... more